Comparative efficacy and safety of chlorthalidone and hydrochlorothiazide-meta-analysis.
Journal
Journal of human hypertension
ISSN: 1476-5527
Titre abrégé: J Hum Hypertens
Pays: England
ID NLM: 8811625
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
11
03
2019
accepted:
14
08
2019
revised:
02
08
2019
pubmed:
9
10
2019
medline:
4
9
2020
entrez:
10
10
2019
Statut:
ppublish
Résumé
Hypertension is a complex syndrome of multiple hemodynamic, neuroendocrine, and metabolic abnormalities. The goals of treatment in hypertension are to optimally control high blood pressure and to reduce associated cardiovascular morbidity and mortality using the most suitable therapy available. Hydrochlorothiazide (HCTZ) and chlorthalidone (CTLD) are with proven hypertensive effects. The topic of our meta-analysis is to compare the efficacy of HCTZ and CTLD therapy in patient with hypertension. A search of electronic databases PubMed, MEDLINE, Scopus, PsyInfo, eLIBRARY.ru was performed. We chose the random-effects method for the analysis and depicted the results as forest plots. Sensitivity analyses were performed in order to evaluate the degree of significance of each study. Of the 1289 identified sources, only nine trials directly compared HCTZ and CTLD and were included in the meta-analysis. Changes in SBP lead to WMD (95% CI) equal to -3.26 mmHg showing a slight but statistically significant prevalence of CTLD. Results from analyzed studies referring to DBP lead to WMD (95% CI) equal to -2.41 mmHg, which is also statistically significant. During our analysis, we found that there were not enough studies presenting enough data on the effect of CTLD and HCTZ on levels of serum potassium and serum sodium. Our meta-analysis has demonstrated a slight superiority for CTLD regarding blood pressure control. At the same time, the two medications do not show significant differences in their safety profile.
Identifiants
pubmed: 31595024
doi: 10.1038/s41371-019-0255-2
pii: 10.1038/s41371-019-0255-2
pmc: PMC6892412
doi:
Substances chimiques
Antihypertensive Agents
0
Sodium Chloride Symporter Inhibitors
0
Hydrochlorothiazide
0J48LPH2TH
Chlorthalidone
Q0MQD1073Q
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
766-774Références
Weber MA, Laragh JH. Hypertension: steps forward and steps backward: the Joint National Committee fifth report. Arch Intern Med. 1993;153:149–52.
doi: 10.1001/archinte.1993.00410020005001
Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure Group. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154–83.
Pool JL, Cushman WC, Saini RK, Nwachuku CE, Battikha JP. Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. Am J Hypertens. 1997;10:117–23.
doi: 10.1016/S0895-7061(96)00323-8
Centers for Disease Control and Prevention. Hypertension. Adanta: Centers for Disease Control and Prevention; 2011. www.cdc.gov/nchs/fastars/hyprtens.htm . Accessed Dec 2011.
Lawes CM, Vander Hoorn S, Rodgers A.International Society of Hypertension Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513–8.
doi: 10.1016/S0140-6736(08)60655-8
Dhalla IA, Gomes T, Yao Z, Nagge J, Persaud N, Hellings C, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med. 2013;158:447–55. https://doi.org/10.7326/0003-4819-158-6-201303190-00004 .
doi: 10.7326/0003-4819-158-6-201303190-00004
pubmed: 23552325
Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57:689–94. https://doi.org/10.1161/HYPERTENSIONAHA.110.161505 .
doi: 10.1161/HYPERTENSIONAHA.110.161505
pubmed: 21383313
Lamb E. Top 200 prescription drugs of 2008. Pharmacy Times. 2009. http://www.pharmacytimes.com/issue/pharmacy/2009/2009-05/RxFocusTop200Drugs-0509 .
Pitt B. The role of chlorthalidone in patients with high-risk hypertension. J Clin Hypertens. 2009;11:460–1.
doi: 10.1111/j.1751-7176.2009.00166.x
Ernst ME, Carter BL, Basile JN. All thiazide-like diuretics are not chlorthalidone: putting the ACCOMPLISH Study into perspective. J Clin Hypertens. 2009;11:5–10.
doi: 10.1111/j.1751-7176.2008.00009.x
Ernst ME, Carter BL, Zheng S, Grimm RH Jr. Meta-analysis of dose response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am J Hypertens. 2010;23:440–6.
doi: 10.1038/ajh.2010.1
Sica DA. Chlorthalidone: a renaissance in use? Expert Opin Pharmacother. 2009;10:2037–9.
doi: 10.1517/14656560903158956
Kaplan NM. The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide. Hypertension. 2009;54:951–3.
doi: 10.1161/HYPERTENSIONAHA.109.135061
Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352–8.
doi: 10.1161/01.HYP.0000203309.07140.d3
Multiple Risk Factor Intervention Trial Research Group. Coronary heart disease death, nonfatal acute myocardial infarction and other clinical outcomes in the multiple risk factor intervention trial. Am J Cardiol. 1986;58:1–13.
doi: 10.1016/0002-9149(86)90232-8
Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616–28.
doi: 10.1161/01.CIR.82.5.1616
Sica DA. Chlorthalidone: has it always been the best thiazide-type diuretic? Hypertension. 2006;47:321–2.
doi: 10.1161/01.HYP.0000203147.75714.ba
Kurtz TW. Chlorthalidone: don’t call it “Thiazide-Like” anymore. Hypertension. 2010;56:335–7.
doi: 10.1161/HYPERTENSIONAHA.110.156166
Neff KM, Nawarskas JJ. Hydrochlorothiazide versus chlorthalidone in the management of hypertension. Cardiol Rev. 2010;18:51–6.
doi: 10.1097/CRD.0b013e3181c61b52
Steber CJ. Differences in chlorthalidone’s mechanism of action vs hydrochlorothiazide and its clinical relevance. EBM Consult; 2015. https://www.ebmconsult.com/articles/chlorthalidone-hydrochlorothiazide-differences-mechanism-of-action#jump_ss_101115 .
Kwon BJ, Jang SW, Choi KY, Kim DB, Cho EJ, Ihm SH, et al. Comparison of the efficacy between hydrochlorothiazide and chlorthalidone on central aortic pressure when added on to candesartan in treatment-naïve patients of hypertension. Hypertens Res. 2013;36:79–84. https://doi.org/10.1038/hr.2012.143 .
doi: 10.1038/hr.2012.143
pubmed: 23034468
Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin-converting—enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–92.
doi: 10.1056/NEJMoa021716
Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–28.
doi: 10.1056/NEJMoa0806182
Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891.
doi: 10.1136/bmj.d4891
Wood R, Brown C, Lockette W. Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis. Hypertension. 2010;56:463–70.
doi: 10.1161/HYPERTENSIONAHA.110.154476
Saseen JJ, Ghushchyan V, Nair KV. Comparing clinical effectiveness and drug toxicity with hydrochlorothiazide and chlorthalidone using two potency ratios in a managed care population. J Clin Hypertens. 2015;17:134–40. https://doi.org/10.1111/jch.12453 .
doi: 10.1111/jch.12453
Bakris GL, Sica D, White WB, Cushman WC, Weber MA, Handley A, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012;125:1229.e1–1229.e10. https://doi.org/10.1016/j.amjmed.2012.05.023 .
doi: 10.1016/j.amjmed.2012.05.023
Pareek A, Basavanagowdappa H, Zawar S, Kumar A, Chandurkar N. A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension. Expert Opin Pharmacother. 2009;10:1529–36. https://doi.org/10.1517/14656560902991514
doi: 10.1517/14656560902991514
pubmed: 19514864
Pareek AK, Messerli FH, Chandurkar NB, Dharmadhikari SK, Godbole AV, Kshirsagar PP, et al. Efficacy of low-dose chlorthalidone and hydrochlorothiazide as assessed by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol. 2016;67:379–89. https://doi.org/10.1016/j.jacc.2015.10.083 .
doi: 10.1016/j.jacc.2015.10.083
pubmed: 26821625
van Blijderveen JC, Straus SM, Rodenburg EM, Zietse R, Stricker BH, Sturkenboom MC, et al. Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide. Am J Med. 2014;127:763–71. https://doi.org/10.1016/j.amjmed.2014.04.014 .
doi: 10.1016/j.amjmed.2014.04.014
pubmed: 24811554
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc. 1991;265:3255–64.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc. 2002;288:2981–97.
doi: 10.1001/jama.288.23.2981
National Heart, Lung and Blood Institute, NIH. Systolic Blood Pressure Intervention Trial (SPRINT) overview. National Heart, Lung and Blood Institute; 2015. http://www.nhlbi.nih.gov/news/spotlight/fact-sheet/systolic-bloodpressure-intervention-trial-sprint-overview .
Sica DA. Diuretic-related side effects: development and treatment. J Clin Hypertens. 2004;6:532–40.
doi: 10.1111/j.1524-6175.2004.03789.x
Khuri RN, Strieder WN, Giebisch G. Effects of flow rate and potassium intake on distal tubular potassium transfer. Am J Physiol. 1975;228:1249–61.
doi: 10.1152/ajplegacy.1975.228.4.1249
Velazquez H, Wright FS. Control by drugs of renal potassium handling. Annu Rev Pharm Toxicol. 1986;26:293–309.
doi: 10.1146/annurev.pa.26.040186.001453
Multiple Risk Factor Intervention Trial Research Group. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the multiple risk factor intervention trial. Am J Cardiol. 1985;55:1–15.
doi: 10.1016/0002-9149(85)90290-5
Liang W, Ma H, Cao L, Yan W, Yang J. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis. J Cell Mol Med. 2017;21:2634–42. https://doi.org/10.1111/jcmm.13205 .
doi: 10.1111/jcmm.13205
pubmed: 28631393
pmcid: 5661252
Ernst ME, Carter BL, Zheng S, Grimm RH Jr. Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am J Hypertens. 2010;23:440–6. https://doi.org/10.1038/ajh.2010.1 . Epub 2010 Jan 28.
doi: 10.1038/ajh.2010.1
pubmed: 20111008
Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension. 2012;59:1104–9. https://doi.org/10.1161/HYPERTENSIONAHA.111.190637 .
doi: 10.1161/HYPERTENSIONAHA.111.190637
pubmed: 22547443
pmcid: 4930655
Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65:1041–6. https://doi.org/10.1161/HYPERTENSIONAHA.114.05021 .
doi: 10.1161/HYPERTENSIONAHA.114.05021
pubmed: 25733245